Igor Vidal
Overview
Explore the profile of Igor Vidal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang F, Liu C, Vidal I, Mana-Ay M, Voter A, Solnes L, et al.
J Nucl Med
. 2023 Dec;
65(1):87-93.
PMID: 38050147
This study aimed to assess the accuracy of intraprostatic tumor volume measurements on prostate-specific membrane antigen-targeted F-DCFPyL PET/CT made with various segmentation methods. An accurate understanding of tumor volumes versus...
2.
Trock B, Jing Y, Mabey B, Sangale Z, Lenz L, Haney N, et al.
J Urol
. 2022 Nov;
208(6):1192-1193.
PMID: 36349916
No abstract available.
3.
Trock B, Jing Y, Mabey B, Sangale Z, Lenz L, Haney N, et al.
J Urol
. 2022 Aug;
208(6):1182-1193.
PMID: 36006048
Purpose: The prognostic value for metastasis of the cell-cycle progression score and phosphatase and tensin homolog haven't been evaluated jointly in contemporary men with exclusively intermediate- or high-risk prostate cancer....
4.
Maynard J, Godwin T, Lu J, Vidal I, Lotan T, De Marzo A, et al.
Prostate
. 2022 Aug;
82(16):1505-1519.
PMID: 35971807
Background: Black men are two to three times more likely to die from prostate cancer (PCa) than White men. This disparity is due in part to discrepancies in socioeconomic status...
5.
Salles D, Asrani K, Woo J, Vidotto T, Liu H, Vidal I, et al.
J Pathol
. 2022 Jan;
257(2):158-171.
PMID: 35072947
GPNMB (glycoprotein nonmetastatic B) and other TFE3/TFEB transcriptional targets have been proposed as markers for microphthalmia (MiT) translocation renal cell carcinomas (tRCCs). We recently demonstrated that constitutive mTORC1 activation via...
6.
Maynard J, Lu J, Vidal I, Hicks J, Mummert L, Ali T, et al.
J Pathol
. 2021 Oct;
256(2):149-163.
PMID: 34652816
Prostate cancer (PCa) remains a leading cause of cancer-related deaths in American men and treatment options for metastatic PCa are limited. There is a critical need to identify new mechanisms...
7.
Vidal I, Zheng Q, Hicks J, Chen J, Platz E, Trock B, et al.
PLoS One
. 2021 Jun;
16(6):e0241934.
PMID: 34191807
GSTP1 is a member of the Glutathione-S-transferase (GST) family silenced by CpG island DNA hypermethylation in 90-95% of prostate cancers. However, prostate cancers expressing GSTP1 have not been well characterized....
8.
Zarif J, Baena-Del Valle J, Hicks J, Heaphy C, Vidal I, Luo J, et al.
Eur Urol Oncol
. 2019 Jul;
2(4):429-436.
PMID: 31277779
Background: M2 tumor-associated macrophages (M2-TAMs) can suppress inflammation in the tumor microenvironment and have been reported to modulate cancer progression. We and others have previously reported M2-TAM infiltration in metastatic...
9.
Gorin M, Rowe S, Patel H, Vidal I, Mana-Ay M, Javadi M, et al.
J Urol
. 2017 Jul;
199(1):126-132.
PMID: 28736318
Purpose: We prospectively evaluated the diagnostic performance of prostate specific membrane antigen targeted F-DCFPyL positron emission tomography/computerized tomography in the preoperative staging of men at high risk for harboring metastatic...